Tigatuzumab Biosimilar – Anti-TNFRSF10B, CD262 mAb – Research Grade from ProteoGenix; catalogue PX-TA1168; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Tigatuzumab Biosimilar – Anti-TNFRSF10B, CD262 mAb is a monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody Tigatuzumab. This biosimilar targets the tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), also known as CD262, which is a cell surface receptor involved in cell death and survival pathways. In this article, we will explore the structure, activity, and potential applications of Tigatuzumab Biosimilar.
Tigatuzumab Biosimilar is a monoclonal antibody, which means it is a type of protein that is produced by a single clone of cells. It is designed to mimic the structure and function of the original therapeutic antibody, Tigatuzumab. The biosimilar is composed of two identical heavy chains and two identical light chains, connected by disulfide bonds. These chains are further divided into variable and constant regions. The variable regions are responsible for binding to the target, while the constant regions determine the effector functions of the antibody.
Tigatuzumab Biosimilar specifically targets TNFRSF10B, a cell surface receptor that is overexpressed in many types of cancer. This receptor is involved in the regulation of cell death and survival pathways, making it an attractive therapeutic target for cancer treatment. By binding to TNFRSF10B, Tigatuzumab Biosimilar blocks its interaction with its ligands, which leads to the activation of cell death pathways and ultimately results in the death of cancer cells.
In addition to its direct anti-tumor activity, Tigatuzumab Biosimilar also has immune-modulating effects. It can activate immune cells, such as natural killer cells and macrophages, to further enhance the destruction of cancer cells. This dual mechanism of action makes Tigatuzumab Biosimilar a promising candidate for cancer therapy.
Tigatuzumab Biosimilar is currently being evaluated in preclinical and clinical studies for its potential use in the treatment of various types of cancer. It has shown promising results in early-phase clinical trials for the treatment of multiple myeloma, a type of blood cancer, as well as solid tumors, such as lung cancer and pancreatic cancer.
The biosimilar is also being investigated for its potential use in combination with other anti- cancer therapies, such as chemotherapy and radiation therapy. Combining Tigatuzumab Biosimilar with these treatments may enhance their efficacy and reduce the risk of resistance development.
In summary, Tigatuzumab Biosimilar – Anti-TNFRSF10B, CD262 mAb is a monoclonal antibody that targets the TNFRSF10B receptor, involved in cell death and survival pathways. Its structure mimics that of the original therapeutic antibody, Tigatuzumab, and it has both direct anti-tumor and immune-modulating effects. This biosimilar is currently being studied for its potential use in the treatment of various types of cancer, either as a standalone therapy or in combination with other treatments. Further research and clinical trials are needed to fully evaluate the efficacy and safety of Tigatuzumab Biosimilar, but it holds great promise as a potential anti- cancer therapy.
ProteoGenix catalogue number PX-TA1168. For research use only.
Target: Tigatuzumab Biosimilar – Anti-TNFRSF10B, CD262 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Tigatuzumab Biosimilar – Anti-TNFRSF10B, CD262 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
